The Discounted Cash Flow (DCF) valuation of Aclaris Therapeutics Inc (ACRS) is (31.14) USD. With the latest stock price at 1.44 USD, the upside of Aclaris Therapeutics Inc based on DCF is -2262.7%.
Based on the latest price of 1.44 USD and our DCF valuation, Aclaris Therapeutics Inc (ACRS) is a sell. selling Aclaris stocks now will result in a potential gain of 2262.7%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 4.8% - 6.3% | 5.6% |
| Long-term Growth Rate | 3.0% - 4.6% | 3.8% |
| Fair Price | (216.00) - (17.13) | (31.14) |
| Upside | -15100.3% - -1289.8% | -2262.7% |